Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

The phase 2, single‐arm, multicenter, open‐label J‐ALTA study evaluated the efficacy and safety of brigatinib in Japanese patients with advanced ALK+ non‐small‐cell lung cancer (NSCLC). One expansion cohort of J‐ALTA enrolled patients previously treated with ALK tyrosine kinase inhibitors (TKIs); th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Tatsuya, Kumagai, Toru, Toyozawa, Ryo, Katayama, Ryohei, Nishio, Makoto, Seto, Takashi, Goto, Koichi, Yamamoto, Nobuyuki, Ohe, Yuichiro, Kudou, Kentarou, Asato, Takayuki, Zhang, Pingkuan, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475780/
https://www.ncbi.nlm.nih.gov/pubmed/37434391
http://dx.doi.org/10.1111/cas.15888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475780/
https://www.ncbi.nlm.nih.gov/pubmed/37434391
http://dx.doi.org/10.1111/cas.15888

Ejemplares similares